Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Johanna Kaufmann
AI-generated illustration
PersonUS

Johanna Kaufmann

Chief scientific officer of Deck Bio, a Massachusetts start-up developing T-cell engagers for solid tumours.

Last refreshed: 14 November 2026

Key Question

Why have T-cell receptor drugs been so hard to make at scale?

Timeline for Johanna Kaufmann

#17 5 Nov

T-Therapeutics raises $133m in Series B

UK Startups and Innovation
View full timeline →

Background

Johanna Kaufmann is chief scientific officer of Deck Bio, an early-stage company in Cambridge, Massachusetts, working on T-cell engagers for solid tumours. She was previously executive vice president of oncology and immunology at Codagenix, and worked on immuno-oncology at GSK after its purchase of Tesaro.

She holds a PhD in cancer virology from the German Cancer Research Center and Heidelberg University.

As T-Therapeutics raised $133m in November 2026 for two T-cell receptor drugs, Kaufmann told BioPharm International that soluble T-cell receptor drugs have "historically" suffered from low manufacturing yields and poor stability. Each such receptor also works only in patients with a matching tissue type, which narrows the market for any one drug.

Common Questions
Who is Johanna Kaufmann of Deck Bio?
Chief scientific officer of Deck Bio, a Cambridge, Massachusetts start-up developing T-cell engagers for solid tumours. She previously led oncology and immunology at Codagenix.Source: BIO International Convention
What are the problems with soluble T-cell receptor drugs?
Johanna Kaufmann told BioPharm International they have historically had low manufacturing yields and poor stability. Each also works only in patients with a matching tissue type.Source: BioPharm International
What does Deck Bio do?
Deck Bio is an early-stage company in Cambridge, Massachusetts, developing T-cell engagers for solid tumours that target several peptides presented on cancer cells.Source: BIO International Convention; Bioprocess Online
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.